Monopar Therapeutics price target raised to $104 from $87 at BTIG

BTIG raised the firm’s price target on Monopar Therapeutics (MNPR) to $104 from $87 and keeps a Buy rating on the shares. The company announced a published letter to the editor by leading Wilson’s disease key opinion leaders in the Journal of Hepatology detailing an updated copper balance analysis from the Phase 2 copper balance study conducted by AstraZeneca (AZN), the analyst tells investors in a research note. The firm says the authors’ conclusions provide an external validation of Monopar’s view that AstraZeneca’s copper balance calculation was flawed, with patient by patient data showing consistent negative trends in copper balance. BTIG believes the update “provides a solid data point” for Monopar to discuss with the FDA as it prepares for a new drug application in early 2026. The firm upped its probability of success for ALXN1840 to 50% from 40%.